No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul

FDA final guidance presents same descriptions of six areas of enforcement priorities – “certain categories of homeopathic drug products marketed without the required FDA approval as potentially posing higher risks to public health” – agency stated in a 2019 revised draft guidance. • Source: Shutterstock
HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation